Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Power Metal renewal; Yamana production hits target

Thu, 13th Jan 2022 21:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Power Metal Resources PLC - London-based metal discoveries company with projects focused in Africa, Australia and North America - Gets renewal of prospecting licences at Molopo Farms Complex project in southwestern Botswana. Power Metal holds a 40% direct project interest in the MFC Project and a 20.65% shareholding in Kalahari Key Mineral Exploration Pty Ltd, which holds the remaining 60% interest. "The renewal of PL310/2016 and PL311/2016 represents an important milestone for the Project, providing a further 2 years for ongoing exploration following the initial successful drilling campaign completed early in 2021," Chief Executive Paul Johnson says.

----------

Yamana Gold Inc - Toronto, Ontario, Canada-based precious metals producer - 2021 gold production rises beats guidance at 884,793 ounces, after 2021 target of 862,000 ounces and higher than 2020's 779,810 ounces. Silver production falls short of guidance, coming in at 9.2 million ounces compared to 2021 target of 10.0 million ounces and was also lower than 2020's 10.4 million ounces. GEO production, which includes gold plus silver at a ratio of 88.86, comes in at 1.0 million - matching guidance.

----------

Rambler Metals & Mining PLC - Canada-focused copper and gold producer, explorer and developer - Finds high-grade mineralisation at Ming copper-gold mine in Canada. Also discovers new zone east of the main lower footwall zone, dubbed LP East zone. "The continued success of our exploration and infill drilling programs provides additional confidence in the resource we have in the ground at the Ming Mine. The diamond drilling completed throughout 2021 has now infilled all production areas for the next 18 months, giving us some breathing room to test exploration targets in addition to continuing the on-going infill drill program," CEO Toby Bradbury says.

----------

Galileo Resources PLC - miner with projects in Botswana, Zambia and South Africa - Says it is conducting an independent review of historical drilling data for the Luansobe copper project in Zambia. Review follows an initial review and is aimed at "compiling all available data into a database to be used to model the extent and tenor of the strata-bound sedimentary copper deposit". Says preliminary analysis suggests that the deposit has a strike length of up to 3 kilometres and extends to a depth of at least 1,250 metres, "with some exceptional drill intercepts". "The initial review of the project suggests that potential exists for a large stand-alone mine since all data suggests that the body is open to depth with considerable strike. We will move aggressively forward with determining the tonnes and grade available for an oxide open pit since this gives us early access to cash flow," says CEO & Chair Colin Bird.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Inks additional agreement with Fosun Pharma, "setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme". Agreement for GBP320,000 to be invoiced on signing with further payments expected, based on services and CTX cell bank vials to be supplied by ReNeuron in the future, "although these are contingent on signing a supplemental payment terms agreement which is currently under discussion". Company will update the market once agreement on the terms have been reached.

----------

Landore Resources Ltd - BAM gold project at Junior Lake in Ontario, Canada - Receives CAD250,000, about GBP145,812, and new shares in Lithoquest Resources Inc worth CAD400,000 in an option deal. Company is also to receive a 2% net smelter returns royalty. Lithoquest retains the right to reduce the NSR to 1% by paying Landore the sum of CAD1.0 million in cash.

----------

Zenith Energy Ltd - Africa-focused production and development energy company - Announces extension to option agreement with Noble Hill-Network Ltd for the purchase of a 42% stake in the Nigerian oil and gas company. Extension is until March 1.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
15 Apr 2014 12:23

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

Read more
15 Apr 2014 10:01

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o

Read more
15 Apr 2014 07:50

UK MORNING BRIEFING: Aggreko Leads After Mixed Results

LONDON (Alliance News) - Aggreko is leading the FTSE 100 in early trading Tuesday after the temporary power company said it has seen mixed results in its first quarter, with strong underlying revenue growth in two of its three regions being impacted by adverse currency movements as previously exp

Read more
27 Mar 2014 13:48

UK MIDDAY BRIEFING: Regulators Confirm UK Energy Market Review

LONDON (Alliance News) - UK regulators have now confirmed they will investigate whether the country's major energy companies are preventing effective competition in the market, a decision that prompted British Gas parent Centrica to warn that the review could delay crucial investments in new i

Read more
27 Mar 2014 13:01

UK WINNERS & LOSERS: Babcock, Tullow Oil Lead Blue-Chip Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.

-------

FTSE 100 - WINNERS

Old Mutual, up 0.5%. The group has agreed to sell Skandia Germany and S

Read more
27 Mar 2014 11:13

ReNeuron Gets Approvals To Begin Two New Trials Using Stem Cell Product

LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product. The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disabi

Read more
14 Mar 2014 13:04

ReNeuron Eyes New UK Government Scheme Encouraging Novel Therapies

LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates. The scheme, called the Early Access to Medicines Scheme, is looking to

Read more
11 Mar 2014 12:48

US foundation funds ReNeuron stem cell therapy

A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward

Read more
11 Mar 2014 11:27

ReNeuron Retinal Stem Cell System Wins FFB Support

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday its retinal stem cell therapy candidate is to receive support from a retinal research funding foundation. ReNeuron said its ReN003 retinal stem cell therapy candidate for the treatment of retinis pigmentosa is set to receive support

Read more
21 Jan 2014 10:04

ReNeuron Sees Positive Data For Stem Cells In Retinal Degeneration Test

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry. The test showed that ReNeuron's cells protected visual function w

Read more
21 Jan 2014 08:19

UK MORNING BRIEFING: Shares Higher; Unilever, SABMiller As Expected

LONDON (Alliance News) - UK shares have opened higher Tuesday, as Unilever and SABMiller have released results and trading statements in line with expectations.

Peel Hunt has issued ratings on the property sector, cutting Great Portland Est

Read more
13 Sep 2013 09:02

ReNeuron Moving All Therapeutic Programmes To Phase II Trials In Next 3 Years

Read more
22 Jul 2013 10:50

ReNeuron announces capital increase, funds to enter capital structure

Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with

Read more
28 May 2013 10:39

ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler

Read more
26 Mar 2013 09:45

ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account